Abbott Pharma withdrew bioresorbable stents from all hospitals in India, claiming “commercial unsustainability” as they need to sell the stents at prices mandated by the NPPA, but the fact is bioresorbable stents have anyway been effectively pulled out from the European market in the wake of several studies showing that bioresorbable cardiac stents are not only “not superior” to existing drug eluting stents (DES), but might even have worse outcomes in some ways.
The pharma co reportedly said it was withdrawing costly BVS as it was not sustainable in the NPPA implemented by Narendra Modi Govt. On the corollary the costly BVS has been also withdrawn from European markets because of increased risk of stent thrombosis and longer duration of use of blood thinners for those implanted with BVS compared to those with DES. These were the risks the studies had highlighted and the co was forced to withdraw the product from there .
Reference :
drashishgupta 